JP2024534471A5 - - Google Patents
Info
- Publication number
- JP2024534471A5 JP2024534471A5 JP2024517059A JP2024517059A JP2024534471A5 JP 2024534471 A5 JP2024534471 A5 JP 2024534471A5 JP 2024517059 A JP2024517059 A JP 2024517059A JP 2024517059 A JP2024517059 A JP 2024517059A JP 2024534471 A5 JP2024534471 A5 JP 2024534471A5
- Authority
- JP
- Japan
- Prior art keywords
- il9ra
- domain
- human
- mouse
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245400P | 2021-09-17 | 2021-09-17 | |
| US202163245386P | 2021-09-17 | 2021-09-17 | |
| US63/245,386 | 2021-09-17 | ||
| US63/245,400 | 2021-09-17 | ||
| PCT/US2022/076611 WO2023044456A1 (en) | 2021-09-17 | 2022-09-16 | Interleukin-9 signaling in chimeric antigen receptor (car) immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534471A JP2024534471A (ja) | 2024-09-20 |
| JP2024534471A5 true JP2024534471A5 (enExample) | 2025-09-17 |
Family
ID=85573151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517059A Pending JP2024534471A (ja) | 2021-09-17 | 2022-09-16 | キメラ抗原受容体（ｃａｒ）免疫細胞におけるインターロイキン－９シグナル伝達 |
| JP2024516765A Pending JP2024534417A (ja) | 2021-09-17 | 2022-09-16 | インターロイキン－９受容体シグナル伝達ドメインを含むキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516765A Pending JP2024534417A (ja) | 2021-09-17 | 2022-09-16 | インターロイキン－９受容体シグナル伝達ドメインを含むキメラ抗原受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230265147A1 (enExample) |
| EP (2) | EP4402163A4 (enExample) |
| JP (2) | JP2024534471A (enExample) |
| KR (2) | KR20240057435A (enExample) |
| AU (2) | AU2022346040A1 (enExample) |
| CA (2) | CA3231615A1 (enExample) |
| IL (2) | IL311206A (enExample) |
| WO (2) | WO2023044456A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020227446A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| EP4402161A1 (en) | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| IL316918A (en) * | 2022-05-09 | 2025-01-01 | Minerva Biotechnologies Corp | Chimeric antigen receptor and IL-18 receptor compositions and methods of using them |
| WO2025039159A1 (en) * | 2023-08-21 | 2025-02-27 | Hangzhou Hervor Therapeutics Co., Ltd | Synthetic cytokine signaling system, preparation method, and uses thereof |
| CN120058904A (zh) * | 2023-11-28 | 2025-05-30 | 中国科学院生物物理研究所 | 一种基于相分离改造嵌合抗原受体的方法及其应用 |
| WO2025132770A1 (en) * | 2023-12-22 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Affitins for the treatment of cancer |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010006111A2 (en) * | 2008-07-10 | 2010-01-14 | Merck & Co., Inc. | Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
| EP2694640B1 (en) * | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| CA3285826A1 (en) * | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| BR112019007100A2 (pt) * | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| CA3154589A1 (en) * | 2018-10-12 | 2020-04-16 | Mauro CASTELLARIN | Compositions and methods for switchable car t cells using surface-bound sortase transpeptidase |
| CN113905757B (zh) * | 2019-06-05 | 2026-01-13 | 中外制药株式会社 | 抗体切割位点结合分子 |
| EP4022035A4 (en) * | 2019-09-01 | 2024-03-27 | Exuma Biotech Corp. | Methods and compositions for the modification and delivery of lymphocytes |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| WO2021141986A1 (en) * | 2020-01-07 | 2021-07-15 | St. Jude Children's Research Hospital, Inc. | Chimeric gmcsf-il18 receptor |
| JP2023520572A (ja) * | 2020-04-06 | 2023-05-17 | シンセカイン インコーポレイテッド | オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞 |
| WO2021244486A1 (zh) * | 2020-06-01 | 2021-12-09 | 上海君赛生物科技有限公司 | 信号转换受体及其用途 |
| EP4305054A4 (en) * | 2021-03-09 | 2025-03-19 | The Trustees of The University of Pennsylvania | SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2 |
| EP4402161A1 (en) * | 2021-09-17 | 2024-07-24 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
-
2022
- 2022-09-16 CA CA3231615A patent/CA3231615A1/en active Pending
- 2022-09-16 CA CA3231618A patent/CA3231618A1/en active Pending
- 2022-09-16 EP EP22870995.2A patent/EP4402163A4/en active Pending
- 2022-09-16 AU AU2022346040A patent/AU2022346040A1/en active Pending
- 2022-09-16 US US17/933,052 patent/US20230265147A1/en active Pending
- 2022-09-16 WO PCT/US2022/076611 patent/WO2023044456A1/en not_active Ceased
- 2022-09-16 US US17/933,049 patent/US20230085834A1/en active Pending
- 2022-09-16 KR KR1020247012564A patent/KR20240057435A/ko active Pending
- 2022-09-16 EP EP22870992.9A patent/EP4402160A4/en active Pending
- 2022-09-16 KR KR1020247012565A patent/KR20240082352A/ko active Pending
- 2022-09-16 JP JP2024517059A patent/JP2024534471A/ja active Pending
- 2022-09-16 WO PCT/US2022/076605 patent/WO2023044453A1/en not_active Ceased
- 2022-09-16 IL IL311206A patent/IL311206A/en unknown
- 2022-09-16 IL IL311356A patent/IL311356A/en unknown
- 2022-09-16 AU AU2022348587A patent/AU2022348587A1/en active Pending
- 2022-09-16 JP JP2024516765A patent/JP2024534417A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534417A5 (enExample) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP2021519580A5 (enExample) | ||
| JP2021514631A5 (enExample) | ||
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2025028239A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JP2021519301A5 (enExample) | ||
| JP2021501570A5 (enExample) | ||
| JP2020506700A5 (enExample) | ||
| JP2017513818A5 (enExample) | ||
| US11725053B2 (en) | Chimeric antigen receptors comprising a human transferrin epitope sequence | |
| JP2019513347A5 (enExample) | ||
| HRP20220767T1 (hr) | Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19 | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016514462A5 (enExample) | ||
| JP2021532742A5 (enExample) | ||
| JP2018521628A5 (enExample) | ||
| HRP20201906T1 (hr) | Označene kimerne efektorske molekule i njihovi receptori | |
| US20220152101A1 (en) | Cellular immunotherapy combination | |
| JP2017519502A5 (enExample) |